Scorpius Holdings, Inc. Announces Pricing of Public Offering
2024年5月14日 - 8:15PM
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the
“Company”), an integrated contract development and manufacturing
organization (CDMO), today announced the pricing of its
underwritten public offering of 60,000,000 common units and/or
pre-funded units in lieu thereof. Each common (or pre-funded) unit
is being offered at a public offering price of $0.10 per unit
(inclusive of the pre-funded warrant exercise price) and consists
of one share of common stock (or pre-funded warrant to purchase one
share of common stock in lieu thereof) and a common warrant to
purchase one share of common stock. The common warrants will have
an exercise price of $0.12 per share and will be immediately
exercisable upon issuance for a period of five years following the
date of issuance. The gross proceeds to the Company from the
offering are expected to be approximately $6,000,000, before
deducting underwriting discounts and offering expenses. In
addition, the Company has granted the underwriters a 45-day option
to purchase up to an additional 9,000,000 shares of common stock
(and/or pre-funded warrants) and/or up to an additional 9,000,000
common warrants solely to cover over-allotments, if any. All of the
shares of common stock (and/or pre-funded warrants) and associated
common warrants are being offered by the Company. The offering is
expected to close on May 16, 2024, subject to satisfaction of
customary closing conditions.
The Company intends to use the net proceeds of
the offering to fund working capital, general corporate purposes,
and the repayment of a $750,000 non-convertible promissory note,
plus accrued and unpaid interest.
ThinkEquity is acting as sole book-running
manager for the offering.
A registration statement on Form S-1 (File No.
333-279092), as amended, including a preliminary prospectus,
relating to the securities being offered was filed with the
Securities and Exchange Commission (“SEC”) and became effective on
May 13, 2024. This offering is being made only by means of a
prospectus. Copies of the preliminary prospectus and final
prospectus, when available, may be obtained from ThinkEquity, 17
State Street, 41st Floor, New York, New York 10004. The final
prospectus will be filed with the SEC and will be available on the
SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Scorpius Holdings,
Inc.Scorpius Holdings Inc. is an integrated large molecule
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking StatementsThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions and include statements regarding the timing and
completion of the proposed offering and the intended use of
proceeds. Important factors that could cause actual results to
differ materially from current expectations include, among others,
the ability to complete the proposed offering, and other factors
described in the Company’s annual report on Form 10-K for the year
ended December 31, 2023 and any other filings the Company makes
with the SEC. The information in this presentation is provided only
as of the date presented, and the Company undertakes no obligation
to update any forward-looking statements contained in this press
release on account of new information, future events, or otherwise,
except as required by law.
For Investor Relations Inquiries:
David Waldman+1
(919)-289-4017investorrelations@nighthawkbio.com
Scorpius (AMEX:SCPX)
過去 株価チャート
から 4 2024 まで 5 2024
Scorpius (AMEX:SCPX)
過去 株価チャート
から 5 2023 まで 5 2024